Ítem
Solo Metadatos

Characterization of adverse drug reactions causing admission to an intensive care unit

Mostrar el registro sencillo de la publicación
dc.creatorRojas?Velandia, Camilospa
dc.creatorRuiz?Garzón, Jairspa
dc.creatorMoscoso?Alcina, Juan?Carlosspa
dc.creatorVallejos?Narvaéz, Álvarospa
dc.creatorCastro?Canoa, Jennyspa
dc.creatorBustos?Martínez, Yurispa
dc.creatorFlórez?Cutiva, Maxspa
dc.creatorContreras?Muñoz, Mabelspa
dc.creatorGómez?Gil, Jully?Carolinaspa
dc.creatorCalderón Ospina, Carlos Alberto
dc.date.accessioned2020-05-26T00:03:36Z
dc.date.available2020-05-26T00:03:36Z
dc.date.created2017spa
dc.description.abstractAims: This study aimed to determine the occurrence of adverse drug reactions (ADRs) that caused admission to the intensive care unit (ICU) of a university hospital. Methods: Clinical records were reviewed for patients meeting the inclusion criteria who were admitted to the ICU between September and December 2012. Suspected cases of ADRs were documented. Nine researchers later evaluated causality using the Naranjo Algorithm, preventability using the Schumock and Thornton criteria, and clinical classification based on the dose–time–susceptibility system. Results: In total, 96 patients presented 108 cases of ADR (13.8%, 95% confidence interval 11.2–16.4%) as the cause of admission. The most frequent ADRs were bradyarrhythmias and upper gastrointestinal bleeding (12%). Therapeutic failure accounted for 20%. The most commonly associated medications were acetylsalicylic acid (16%) and losartan (10%). Forty-six cases were categorized as possible, and only one as definite. According to the dose–time–susceptibility classification, in 82% of the cases, the dosage was collateral (within the therapeutic range), and 90% were independent of time; the factors most associated with susceptibility to ADRs were comorbidities (42%) and age (49%). Forty-four percent of the ADRs were considered possibly preventable. Conclusions: ADRs contribute significantly to ICU admissions, and a significant number of ADRs are preventable. National studies are needed to assess their incidence and to establish classification standards to reduce their clinical impact. © 2016 The British Pharmacological Societyeng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1111/bcp.13199
dc.identifier.issn13652125
dc.identifier.issn03065251
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23609
dc.language.isoengspa
dc.publisherBlackwell Publishing Ltdspa
dc.relation.citationEndPage1140
dc.relation.citationIssueNo. 5
dc.relation.citationStartPage1134
dc.relation.citationTitleBritish Journal of Clinical Pharmacology
dc.relation.citationVolumeVol. 83
dc.relation.ispartofBritish Journal of Clinical Pharmacology, ISSN:13652125, 03065251, Vol.83, No.5 (2017); pp. 1134-1140spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85009508831&doi=10.1111%2fbcp.13199&partnerID=40&md5=29634f38ec80b6c1a63b9fab9d52d2a6spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAcetylsalicylic acidspa
dc.subject.keyworduniversityeng
dc.subject.keywordBromocriptinespa
dc.subject.keywordCapecitabinespa
dc.subject.keywordCarbamazepinespa
dc.subject.keywordCarvedilolspa
dc.subject.keywordClonidinespa
dc.subject.keywordClopidogrelspa
dc.subject.keywordContrast mediumspa
dc.subject.keywordDalteparinspa
dc.subject.keywordDigoxinspa
dc.subject.keywordEnalaprilspa
dc.subject.keywordEnoxaparinspa
dc.subject.keywordEtanerceptspa
dc.subject.keywordFurosemidespa
dc.subject.keywordHydrochlorothiazide plus spironolactonespa
dc.subject.keywordIbuprofenspa
dc.subject.keywordIsophane insulinspa
dc.subject.keywordLosartanspa
dc.subject.keywordMethylprednisolonespa
dc.subject.keywordMetoprololspa
dc.subject.keywordMorphinespa
dc.subject.keywordMycophenolic acidspa
dc.subject.keywordNaproxenspa
dc.subject.keywordNebivololspa
dc.subject.keywordPhenobarbitalspa
dc.subject.keywordPhenytoinspa
dc.subject.keywordPig insulinspa
dc.subject.keywordUnindexed drugspa
dc.subject.keywordValproic acidspa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordAdverse drug reactionspa
dc.subject.keywordAgedspa
dc.subject.keywordAlgorithmspa
dc.subject.keywordArticlespa
dc.subject.keywordAscitesspa
dc.subject.keywordBradycardiaspa
dc.subject.keywordCerebrovascular diseasespa
dc.subject.keywordChronic kidney failurespa
dc.subject.keywordClassificationspa
dc.subject.keywordComorbidityspa
dc.subject.keywordDeliriumspa
dc.subject.keywordDiabetic ketoacidosisspa
dc.subject.keywordDisease exacerbationspa
dc.subject.keywordDrug treatment failurespa
dc.subject.keywordFemalespa
dc.subject.keywordGastrointestinal hemorrhagespa
dc.subject.keywordGroups by agespa
dc.subject.keywordHeart blockspa
dc.subject.keywordHospital admissionspa
dc.subject.keywordHumanspa
dc.subject.keywordHyperkalemiaspa
dc.subject.keywordHypoglycemiaspa
dc.subject.keywordHypotensionspa
dc.subject.keywordImmune deficiencyspa
dc.subject.keywordIntensive care unitspa
dc.subject.keywordLeukopeniaspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMalespa
dc.subject.keywordPriority journalspa
dc.subject.keywordRespiration depressionspa
dc.subject.keywordSeizurespa
dc.subject.keywordSubarachnoid hemorrhagespa
dc.subject.keywordSubdural hematomaspa
dc.subject.keywordThrombocytopeniaspa
dc.subject.keywordUniversity hospitalspa
dc.subject.keywordUpper gastrointestinal bleedingspa
dc.subject.keywordVery elderlyspa
dc.subject.keywordAdverse drug reactionspa
dc.subject.keywordDose responsespa
dc.subject.keywordHospitalizationspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordRetrospective studyspa
dc.subject.keywordTime factorspa
dc.subject.keywordYoung adultspa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordAged, 80 and overspa
dc.subject.keywordDose-response relationshipeng
dc.subject.keywordDrug-related side effects and adverse reactionsspa
dc.subject.keywordFemalespa
dc.subject.keywordHospitalizationspa
dc.subject.keywordHospitalseng
dc.subject.keywordHumansspa
dc.subject.keywordIntensive care unitsspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordRetrospective studiesspa
dc.subject.keywordTime factorsspa
dc.subject.keywordYoung adultspa
dc.subject.keywordDrug-related side effects and adverse reactionsspa
dc.subject.keywordIntensive care unitsspa
dc.subject.keywordPatient admissionsspa
dc.subject.keywordPharmacovigilancespa
dc.subject.keywordPostmarketingspa
dc.subject.keywordProduct surveillancespa
dc.titleCharacterization of adverse drug reactions causing admission to an intensive care unitspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos